ALIVUS1,390.00

Alivus Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAARTIDRUGSAKUMSAGARWALEYEAPLLTDADVENZYMESAARTIPHARMCORONA
View
In ₹ Crore except Per Share
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation37.942.153.5
+ Finance Costs28.00.51.5
+ Interest Income-6.8-15.8-12.0
Changes in Working Capital
+ Inventories-2.8-87.9-82.6
+ Trade Receivables — Current-59.2-133.637.9
+ Trade Payables — Current73.798.2-34.1
Cash from Operating Activities
Profit Before Tax (per I/S)564.9628.6631.3800.6
Cash from Operations (pre-tax)735.8467.0576.5
Cash from Operating Activities597.6313.4413.5
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)132.2170.2129.0
+ Disp of Fixed Assets0.50.20.5
+ Interest Received — Investing6.715.812.0
Cash from Investing Activities-122.2-154.1-116.5
Cash from Financing Activities
+ Proceeds from Borrowings960.6
+ Payment of Lease Liabilities1.41.62.2
+ Interest Paid0.1
+ Dividends Paid128.7385.9275.7
Cash from Financing Activities-78.8-387.6-279.4
Net Changes in Cash396.6-228.317.6
Reference Items
EBITDA616.1642.3674.2836.7
EBITDA Margin %29.0229.7229.5332.30
Free Cash Flow (CFO − Capex)465.4143.2284.5284.5
Cash Flow to Net Income1.430.670.88
Cash Paid for Interest0.1
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.